Provided by Tiger Trade Technology Pte. Ltd.

TELA Bio, Inc.

0.9113
+0.08129.78%
Volume:298.29K
Turnover:264.11K
Market Cap:40.80M
PE:-1.17
High:0.9400
Open:0.8300
Low:0.8300
Close:0.8301
52wk High:1.70
52wk Low:0.5011
Shares:44.77M
Float Shares:21.52M
Volume Ratio:1.25
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7776
EPS(LYR):-0.8300
ROE:-616.62%
ROA:-33.40%
PB:-2.57
PE(LYR):-1.10

Loading ...

TELA Bio Announces Special Shareholder Meeting

Reuters
·
Sep 05

Analyst Reaffirms Buy on TELA Bio, Citing Restructuring-Driven Cost Savings and Steady $2 Price Target

TIPRANKS
·
Sep 01

TELA Bio - Roberto Cuca Steps Down as COO and CFO Effective August 31, 2026

THOMSON REUTERS
·
Aug 31

TELA Bio - Anticipates One-Time Restructuring Charge of About $1.50 Mln in Q3 2026

THOMSON REUTERS
·
Aug 31

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

THOMSON REUTERS
·
Aug 31

TELA Bio - to Reduce Headcount by About 20%

THOMSON REUTERS
·
Aug 31

TELA Bio - to Reduce Annual Operating Expenses by About $17 Mln

THOMSON REUTERS
·
Aug 31

TELA Bio - Expects Cost Reduction Initiative to Extend Cash Runway into 2028

THOMSON REUTERS
·
Aug 31

TELA Bio CEO Heather Getz Acquires 12,500 Common Shares Valued at $8,311.25

Reuters
·
Aug 20

TELA Bio CEO Makes Bold Move Signaling Fresh Confidence in the Company

TIPRANKS
·
Aug 18

TELA Bio CEO Heather C. Getz Acquires Common Shares Worth $10,467

Reuters
·
Aug 18

Tenon Medical Q2 Revenue Jumps on Higher Surgical Procedure Volume

Reuters
·
Aug 14

TELA Bio Amends 8-K to Detail Former CEO Koblish Separation Benefits

Reuters
·
Aug 14

Sanara MedTech Q2 Revenue Rises on Soft-Tissue Product Growth

Reuters
·
Aug 12

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Sonida Senior Living (SNDA) and TELA Bio (TELA)

TIPRANKS
·
Aug 11

Xtant Medical Q2 Revenue Falls on Asset Sales and Lost License Revenue

Reuters
·
Aug 11

Piper Sandler Sticks to Its Hold Rating for TELA Bio (TELA)

TIPRANKS
·
Aug 11

TELA Bio Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

TELA Bio Q2 Revenue Falls on Lower OviTex PRS Volumes, Withdraws Outlook

Reuters
·
Aug 11

TELA Bio Q2 FY26 Net Loss Widens to $11.3 Million; Revenue Drops 4% to $19.3 Million

Reuters
·
Aug 11